^
TNFRSF8 positive
Cutaneous T-cell Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
No biomarker
Cutaneous T-cell Lymphoma
bexarotene oral
Sensitive: A1 - Approval
No biomarker
Cutaneous T-cell Lymphoma
vorinostat
Sensitive: A1 - Approval
IL2RA expression
Cutaneous T-cell Lymphoma
denileukin diftitox
Sensitive: A1 - Approval
No biomarker
Cutaneous T-cell Lymphoma
denileukin diftitox
Sensitive: A1 - Approval
No biomarker
Cutaneous T-cell Lymphoma
RP6530
Sensitive: B - Late Trials
TNFRSF8 expression
Cutaneous T-cell Lymphoma
brentuximab vedotin
Sensitive: C1 - Off-label
PD-L1 underexpression
Cutaneous T-cell Lymphoma
durvalumab + lenalidomide
Sensitive: C3 – Early Trials
RPS6 underexpression
Cutaneous T-cell Lymphoma
ruxolitinib
Sensitive: C3 – Early Trials
ICOS underexpression
Cutaneous T-cell Lymphoma
durvalumab
Sensitive: C3 – Early Trials
PD-1 overexpression
Cutaneous T-cell Lymphoma
pembrolizumab
Sensitive: C3 – Early Trials